Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q – IMPROVE CODEL: the NOA-18 trial

BACKGROUND: Given the young age of patients with CNS WHO grade 2 and 3 oligodendrogliomas and the relevant risk of neurocognitive, functional, and quality-of-life impairment with the current aggressive standard of care treatment, chemoradiation with PCV, of the tumour located in the brain optimizing...

Descripción completa

Detalles Bibliográficos
Autores principales: Wick, A., Sander, A., Koch, M., Bendszus, M., Combs, S., Haut, T., Dormann, A., Walter, S., Pertz, M., Merkle-Lock, J., Selkrig, N., Limprecht, R., Baumann, L., Kieser, M., Sahm, F., Schlegel, U., Winkler, F., Platten, M., Wick, W., Kessler, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9190129/
https://www.ncbi.nlm.nih.gov/pubmed/35692047
http://dx.doi.org/10.1186/s12885-022-09720-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9190129/
https://www.ncbi.nlm.nih.gov/pubmed/35692047
http://dx.doi.org/10.1186/s12885-022-09720-z

Ejemplares similares